CANDITRAL is a new orally active triazole antifungal drug with a broad spectrum of activity and a favourable pharmacokinetic profile. It is a potent inhibitor of most human fungal pathogens and is extremely effective in a wide range of superficial and serious deep sealed fungal infections when administered once or twice daily.
CANDITRAL is a promising drug for prophylaxis of opportunistic fungal infections in women with chronic recurrent vaginal candidiasis, immunodeficient patients with chronic mucocutaneous candidiasis, AIDS patients and patients receiving immunosuppressant drugs.